Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Survey Study for Velaglucerase Alfa (VPRIV) in Japan
The objective of this post-marketing survey study is to collect data to determine the safety
 and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new
 to therapy or have been switched from another therapeutic agent for Gaucher disease.
Inclusion Criteria:

 -  Male or female participants with a confirmed diagnosis of Gaucher disease

 -  Participants who are either naïve to treatment or participants that have been treated
 with another therapeutic agent for Gaucher disease

 -  Participants who start VPRIV treatment or transition from VPRIV clinical studies
 during the enrollment period

 Exclusion Criteria:

 -